AZD0156

AZD0156 is an orally bioavailable small molecule inhibitor of ataxia telangiectasia mutated (ATM) kinase. ATM is a serine/threonine protein kinase that plays a central role in the DNA damage response (DDR), particularly in the repair of double-strand DNA breaks. By inhibiting ATM kinase activity and its downstream signaling pathways, AZD0156 disrupts DNA damage checkpoint activation and impairs DNA repair mechanisms. This leads to increased tumor cell apoptosis and enhances the cytotoxic effects of chemotherapy and radiotherapy by sensitizing cancer cells to these treatments. Preclinical studies have shown that AZD0156 can potentiate the efficacy of agents such as irinotecan and PARP inhibitors like olaparib across various cancer models. The drug was developed primarily for use in advanced solid tumors[1][2][3][4][5][6].

Other names

8-(6-(3-(Dimethylamino)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one1821428-35-6